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Background: In the nursing home population, it is estimated that 1 in every 3 patients is polymedicated and given
their considerable frailty, these patients are especially prone to adverse drug reactions. Clinical pharmacist-led
medication reviews are considered successful interventions to improve medication safety in the inpatient setting.
Due to the limited available evidence concerning the benefits of medication reviews performed in the nursing
home setting, we propose a study aiming to demonstrate a positive effect that a clinical decision support system,
as a health care intervention, may have on the target population. The primary objective of this study is to reduce
the number of patients with at least one event when using the clinical decision support system compared to the
regular care. These events consist of hospital referrals, delirium, falls, and/or deaths.
Method/Design: This study is a multicentre, prospective, randomised study with a cluster group design. The
randomisation will be per main nursing home physician and stratified per ward (somatic and psychogeriatric).
In the intervention group the clinical decision support system will be used to screen medication list, laboratory
values and medical history in order to obtain potential clinical relevant remarks. The remarks will be sent to the
main physician and feedback will be provided whether the advice was followed or not. In the control group
regular care will be applied.
Discussion: We strongly believe that by using a clinical decision support system, medication reviews are performed in
a standardised way which leads to comparable results between patients. In addition, using a clinical decision support
system eliminates the time factor to perform medication reviews as the major problems related to medication,
laboratory values, indications and/or established patient characteristics will be directly available. In this way, and
in order to make the medication review process complete, consultation within healthcare professionals and/or
the patient itself will be time effective and the medication surveillance could be performed around the clock.
Trial registration: The Netherlands National Trial Register NTR5165. Registered 2nd April 2015.
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Polypharmacy is defined as the use of more than a cer-
tain number of drugs irrespective of their appropriate-
ness [1, 2]. In the Netherlands, it has been defined as the
chronic use of 5 or more drugs from different thera-
peutic groups or subgroups [3]. In the nursing home
population, it is estimated that 1 in every 3 patients is
polymedicated [4] and given their considerable frailty,
these patients are extra prone to adverse drug reactions.
In addition, their management is often challenging given
the comorbidities and/or complex organ function impair-
ment [1, 2, 5–8]. Furthermore, polymedicated patients are
also at risk of suffering from inappropriate prescribing in
the form of underprescription. It has been demonstrated
that underprescription increases significantly with the
number of medicines used [9]. This situation strengthens
the need for routine medication reviews and treatment
optimisation [10, 11].
Clinical pharmacist-led medication reviews are consid-
ered successful interventions to improve medication safety
in the inpatient setting. However, there is limited available
evidence of the effects concerning comparable interven-
tions performed in the outpatient setting [1, 12, 13]. In
addition, few studies have evaluated health related out-
comes resulting from clinical pharmacist interventions
in nursing homes. Nevertheless, it has been suggested
that most of these studies had major limitations: no
control group, no clinical outcome measures, inadequate
use of nursing staff to influence change, and data analysis
by drug use per provider rather than drug use per patient
[6, 8, 10, 11, 13, 14]. Some of these studies were rando-
mised controlled trials performed in the nursing home
setting by means of a clinical pharmacists-led medication
review; some of them measured the effect of multi-
disciplinary case conference [6, 15]. In other studies,
pharmacists performed the medication reviews and sent
suggestions to physicians [8, 10, 16]. Nevertheless, some
improvements in patient outcomes have been described
[8, 10]. The results from these studies are difficult to
compare due to the large differences with respect to the
interventions applied, the outcomes studied, the settings,
and duration of follow-up after the medication review.
Pharmacotherapy optimisation in nursing home
patients relies on the development and assessment of
novel healthcare interventions [11]. It is suggested that
performing a standardised intervention could potentially
lead to a successful medication review; this intervention
necessitates pharmacists and physicians collaboration, it
should include the complete medical and drug history,
and fully availability of laboratory values should be guar-
anteed [10, 12, 13, 17–20].
In the Netherlands, the Dutch Healthcare Inspectorate
(IGZ: Inspectie voor de Gezondheidszorg) expects that a
medication review is performed by a physician and apharmacist in all residents of nursing homes yearly;
however, this advice implies substantial extra workload
for the involved health care professionals. In addition, in
this medication review the information given by the
nursing staff and the patient him/herself should also be
taken into account.
From our experience, medication reviews involve a
time consuming process that takes an average of 90 min
per patient. When considering a nursing home of about
150 patients, 450 h a year would have to be dedicated at
performing medications reviews.
In daily practice, this unfortunate situation leads to a
non-continuous medication review process implying
major consequences that may range from an increased
number of potential adverse drug reactions, unnecessary
hospitalisations and, at worst, death.
Computerised clinical decision support systems
(CCDSS) can be defined as decision-aiding tools which
provide health care professionals with clinical knowledge
and patient-related information, intelligently filtered or
presented at appropriate times, so as to enhance patient
care [21–23]. Within the SCREEN project (Supporting
Clinical Rules in the Evaluation of Elderly patients with
Neuropsychiatric disorders), a CCDSS named Clinical
Rule Reporter (CRR) has been developed. This system
currently analyzes, independently of the applied pre-
scribing software, the medication used by patients in rela-
tion to their co-medication, the laboratory data (including
renal function), and other relevant clinical data like diag-
nosis and comorbidities [24]. The CRR combines the
clinical rules (algorithms) with the medication list,
patient characteristics and laboratory values of the pa-
tients in order to obtain concrete advices. These clinical
rules or algorithms work with triggers that identify drug
related problems like renal or liver dysfunction as well
as the need of new medication (stomach protection or
laxative agents), the necessity to stop a certain drug or
decrease the dose according to age, etc.
Due to the lack of evidence concerning the benefits
of medication reviews performed in the nursing home
setting, we propose a study aiming to demonstrate a
positive effect that the CRR, as a health care interven-
tion, may have on the target population. This popula-
tion consists of older people (≥65 years) with a high
risk of suffering harm when using inappropriate drugs.
By this we mean people living in nursing home facil-
ities; these people often suffer from polymedication
among other risk factors such as multimorbidity,
impaired cognition, renal dysfunction, and increased
risk of falling.
The primary objective of this study is to reduce the
number of patients with at least one event when using
the CRR compared to the regular care. These events
consist of hospital referrals, delirium, falls, and/or
Mestres Gonzalvo et al. BMC Geriatrics  (2017) 17:35 Page 3 of 8deaths. Secondary objectives will also be evaluated,
including: the analysis within a centre to account for
possible differences concerning regular care, the separate
analysis for psychogeriatric and somatic wards, the ana-
lysis for medication related events (hospital referrals,
delirium, falls, and/or deaths), the separate analysis for
each of the parameters included in the combined end-
point, the analysis of the quality of life EQ-5D, the analysis




The Supporting Clinical Rules Engine in the Adjustment
of Medication (SCREAM) study is a multicentre, pro-
spective, randomised study with a cluster group design.
The randomisation will be per main nursing home phys-
ician and stratified per ward (somatic and psychogeriatric).
This study will be blinded for physicians and for patients;
physicians will be emphatically requested not to discuss
with each other about the study to avoid bias. The study
follows the CONSORT guidelines.
Overall study design
In order to use the CRR, the nursing homes will have to
provide the medication list, the patient characteristics
and the laboratory values for each patient in a digital
format.
Taking into account the extra workload for the investi-
gators, there will be a predefined day for each nursing
home to send the files: nursing home A sends the files on
Mondays, nursing home B sends the files on Tuesday, and
so on.
All nursing homes will send the patient data both for
control and intervention groups.
The randomisation will be performed by two of the
authors (BvO, CMG). The randomisation will be per
main nursing home physician and stratified per ward.
Physician A will be randomised in the control group and
physician B on the intervention group, taking into ac-
count that the amount of patients in each group should
be approximately the same.
Intervention group
The datasets will be screened through the CRR on a weekly
basis. The messages delivered by the CRR will be sent via
mail to the specific physicians. Each remark will be sent
on a separate mail in a standardised way. In response to
the report, the physician will send a feedback message
within 36 h indicating, in a standardised way, whether:
– the advice was not followed
– the advice was followed
– the advice was changed.After receiving this feedback, the investigators will
process it in the CRR, in order to create the database for
the study.
Additionally, regular care will be also applied. That is
according to the Dutch Healthcare Inspectorate, a yearly
medication review with a physician and a pharmacist,
even though there is a substantial variation [25], For the
centres included in this study there are no dedicated
clinical pharmacist working in the nursing home.
Control group
In the control group patients will receive regular care
(yearly medication review). In addition, these patients
will also be screened using the CRR to obtain data that
could serve for future evaluations within the project (for
instance to compare how many advices would have been
sent from the control group, the difference in remarks,
etc.). However, this screening will be performed via a
filter and the investigators will neither see nor evaluate
any remark. These alerts will only be unblinded at the
end of the study.
In addition, for both control and intervention group,
the physicians will report any events including: hospital
admission, specialist visit, emergency department visit,
falls, delirium and death, via a questionnaire. This ques-
tionnaire will also include questions to know whether a
medication review has been performed and how much
time this medication review cost. Physicians will also
report if there is any new patient. These electronic ques-
tionnaire will be sent by Google Drive via email weekly.
At the end of the study, the physicians in the interven-
tion group will receive a mail asking how much time, in
average, they need to answer the remarks which are sent
from the CRR. Figures 1 and 2.
Endpoints
Primary endpoint The primary outcome variable in this
study is the proportion of patients with at least one of
the events, including hospital referrals (i.e. referral to a
specialist, emergency department visit and hospital
admission), delirium, falls, and/or deaths. All these
events will be reported by the nursing home physician
via the electronic questionnaire. To this end the study
will assess the differences between regular care (control
group) and regular care + CRR (intervention group).
Secondary endpoints As secondary endpoints, the same
outcome variable will be used to analyse the possible
differences between institutions, to separately analyse
psychogeriatric and somatic wards, to analyse the medi-
cation related events, and to separately analyse each of
the parameters included in the combined endpoint (hos-
pital referrals, delirium, falls, and/or deaths).
Fig. 1 Schematic study design. *Other possible centres Amsterdam and Nijmegen
Fig. 2 Study schedule
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to report any events including: hospital admission, poly-
clinic visit, emergency department visit, falls, delirium
and death. These questions will be asked via an elec-
tronic questionnaire via Google Drive. The assessment
of whether the event is or could be drug related or not
will be done exclusively by the physician.
The quality of life will be measured using the EQ-5D
questionnaire both for patients in the control group and
patients in the intervention group. The questionnaire
will be performed at the end of the study (i.e. after one
year follow-up), both for psychogeriatric and somatic
patients. The results will be compared between interven-
tion and control group. For both patients groups a care-
giver/nurse will answer the questionnaire.
In addition the analysis of the MAI and the cost
evaluation will also be performed for both control and
intervention group.
Setting
Nursing homes in the Netherlands will be invited to par-
ticipate in the study; these nursing homes should be able
to deliver the medication data and the laboratory data
electronically. In case the data would come from the
hospital in the neighbourhood, this hospital would have
to agree on providing the data. If a nursing home meets
these requirements, it is eligible for participation in the
present study.
Population
Nursing home residents; the total study population is
estimated to have a total of 3500–4500 patients. This
wide range in amount of patients comes from the fact
that patients will not be included singly but as complete
nursing homes. In addition, enough patients should be
included to ensure reliable results taking into account
possible loss to follow up.
Inclusion criteria
Residents living in a nursing home in the Netherlands.
The nursing homes are able to deliver the medication
and lab data electronically.
Participating centres
Zuyderland Medical Centre in Sittard-Geleen (coordinat-
ing centre), Envida in Maastricht, Sevagram in Heerlen,
Elkerliek in Helmond, and Novicare in different locations.
Other centres will be invited and included when the
requirements are fulfilled (Amsterdam and Nijmegen).
Randomisation, blinding and treatment allocation
Randomisation
per main nursing home physician. The randomisation
will be stratified per ward (somatic and psychogeriatric).In case the physician would be absent the suitable
option will be followed:
Absence ≤ 6 weeks intervention group: the mails with
the messages obtained from the CRR will still be sent to
the main physician. If the replacing physician would also
participate in the study, he will not get any mails for the
group of patients for which he/she is the replacing
physician during this period. It is assumed that if the
replacing physician is included in the intervention
group, he could apply the mails from his own group to
all patients. If the replacing physician is included in the
control group, it is assumed that no interventions will
be performed.
Absence > 6 weeks intervention group: the mails will
be sent to the replacing physician; if the replacing phys-
ician would be one of the physicians already included
and randomised in the control group, the replacing
physician will get the mails only for the patients in the
intervention group.Blinding
Blinded for patients; In addition, physicians will be
emphatically requested not to talk about the emails.Treatment allocation
If a patient dies or moves to another institution, the
replacing patient will not take over the place in the
study. Death is one of the endpoints for the study and so
the study would be completed for that patient; moving
to another institution will be considered as loss to
follow-up. To account for these patients the physicians
will have to report every time a new patient gets in the
nursing home, in this way a filter can be applied to not
analyse these new patients.Time schedule
Recruitment started in June 2013; the target population,
3500–4500 patients, is expected to be accomplished in
June 2016. The different centres can start with the study
at different times. Each centre will be followed for a
period of 1 year and afterwards the data analysis will
start.Organisation
Each participating centre has provided a contact person
who will be in charge of coordinating the study in their
centres. The investigators have regular contact with
these coordinating people to confirm the fulfilment of
the inclusion criteria, the adherence to the study proto-
col, and to provide support or additional information
when necessary.
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A cost analysis will be performed for both groups (con-
trol and intervention).Hospital costs
The analysis will take into account the number of hospi-
talisations or hospital referrals, consisting of personnel
(physician, nurse, pharmacists, etc.), material and equip-
ment costs. These costs will be based on study patients
records and standard rates.Costs outside the hospital
This analysis will also take into account the healthcare
costs outside the hospital like the addition of new
medication.Sample size calculation
Calculation of the total number (one event per patient).
The aim is to reduce the number of patients with at least
one event with 25% by using the CRR compared to the
regular care. These events consist of medication related
hospital referrals, delirium, falls, and/or deaths.
In order to calculate the sample size a pilot study was
performed. Nursing homes physicians from the region
(Envida and Zuyderland) have informed, via an electronic
questionnaire, about any hospital referrals, delirium and/
or falls within their patients. In addition, they stated
whether these events could be medication related. This
pilot study has lasted for 5 months. No patient informa-
tion was given.
The pilot study showed a proportion of patients with
at least one event (combination of fall, delirium, hospital
referral, and death) in the control group of 0.16 and a
mean number of patients per physician of 56.
Assuming a proportion of patients with at least 1
event during 1 year follow-up of 0.20 in the control
group, a 25% reduction by using the CRR compared to
regular care, i.e. proportion reduces from 0.20 to 0.15,
and a two-sided significance level (α) of 0.05, the num-
ber of patients per group required to detect an effect
with 80% power equals 906. Accounting for the design
effect (randomisation per physician; DE = 1 + (m-1)*ICC),
where we assume an intra-class correlation coefficient
(ICC) of 0.01, a mean number of patients per physician
(m) of 56 (pilot study), and a 10% dropout rate, the
required number of patients increases to 1562 per group.
We assumed a higher proportion of patients with at
least one event in the control group (0.20) than the one
found in the pilot study (0.16), because the number of
falls were underreported in the pilot study and the
follow-up duration is now longer, i.e. one year instead of
five months.Statistical analysis
To account for the cluster randomisation (physicians are
randomised, where patients are clustered within physi-
cians), all linear and logistic mixed effects analyses are
performed with physicians as random factor.
Primary study parameters
To detect a difference in proportions of the primary out-
come (composite endpoint consisting of hospital refer-
rals, delirium, falls, and/or deaths) between the groups
(control versus intervention), logistic mixed effects ana-
lysis are applied with the following fixed factors: group
(control or intervention), nursing home organisation
(Envida, Zuyderland, Sevagram or Novicare), type of
ward (psychogeriatric or somatic) and other variables
related to the outcome, like age and sex.
Secondary study parameters
For the subgroup analyses (within nursing home organ-
isation or within type of ward), the same analysis
method is applied as for the primary outcome variable,
excluding the variable that indicates the subgroups.
For the other endpoints, linear or logistic mixed
models are used, depending on the type of outcome
(numerical or binary, respectively). Furthermore, the
same fixed effects as for the primary outcome are
included.
Discussion
Other studies have mainly focused on surrogate out-
comes as primary endpoint. These endpoints, such as
reduction of drugs, MAI or drug costs, fail at showing
clinical outcomes [10, 12, 15, 26–29]. In the present
study, we are focusing both on hard endpoints (i.e. pa-
tient relevant outcomes), and surrogate outcomes. The
primary endpoint, however, is a combined set of hard
endpoints with a clear clinical outcome. For this reason,
the duration of this study is one year; other studies not
using hard endpoints have shorter study periods [6, 8,
10, 29]. Furthermore, this study is a multicentre study
including over 3000 patients making it a relatively large
study in comparison with other studies [6, 8, 10, 27, 28].
A major discussion point with other articles is the fact
that a great number of studies focus on reducing the
amount of prescribed drugs whereas the focus should be
on optimising the prescribed drugs (rationalistic pharma-
cotherapy). This fact enlightens the paradoxically relation
between polypharmacy and underprescribing as it might
be confronting to add new medication to an already poly-
medicated patient whereas reducing medication might
seem the most logical way to perform [9]. For some
patients, optimising the medication will imply reducing
the number of drugs, for other patients it will be the chan-
ging of some drugs or adding some drugs [30].
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reviews are performed in a standardised way which leads
to comparable results between patients. In addition, using
a CCDSS eliminates the time factor to perform medica-
tion reviews as the major problems related to medication,
laboratory values, indications and/or established patient
characteristics will be directly available. In this way, and in
order to make the medication review process complete,
consultation within healthcare professionals and/or the
patient itself will be time effective and the medication sur-
veillance could be performed around the clock. Especially
for polymedicated patients, like nursing home patients,
this system provides a hand full of advantages to pro-
vide continuous surveillance, improving in this way
patient care.
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